Welcome to our dedicated page for Indivior Pharmaceuticals SEC filings (Ticker: INDV), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Indivior PLC (NASDAQ: INDV) SEC filings page on Stock Titan provides direct access to the company’s regulatory disclosures as filed with the U.S. Securities and Exchange Commission. As a pharmaceutical issuer focused on opioid use disorder (OUD) treatments, Indivior uses its filings to report financial results, strategic initiatives, governance changes, and key legal and regulatory matters.
Investors can review Form 8-K current reports in which Indivior details material events such as quarterly financial results, updates on the Indivior Action Agenda, restructuring charges, optimization of its Rest of World business, and changes to executive compensation or board composition. Other 8-K items describe the company’s intent to redomicile from the U.K. to Delaware, shareholder approvals of a scheme of arrangement and amended articles of association, and the conclusion of a legacy U.S. Department of Justice resolution agreement.
Through its periodic reports (Forms 10-K and 10-Q, when available on EDGAR), readers can examine segment performance, revenue composition, R&D spending, and risk factors related to Indivior’s OUD-focused portfolio, including SUBLOCADE, SUBOXONE Film, PERSERIS, and OPVEE. These filings also typically include detailed discussions of non-GAAP measures such as adjusted EBITDA and non-GAAP operating expenses, along with reconciliations to U.S. GAAP metrics.
Stock Titan enhances these documents with AI-powered summaries that highlight the most important points in lengthy filings, helping users quickly understand changes in guidance, restructuring actions, legal exposures, or capital structure. Real-time updates from EDGAR mean that new Indivior filings, including any future proxy statements on executive compensation and Form 4 insider transaction reports, are surfaced promptly.
By using this page, investors, analysts, and other stakeholders can efficiently navigate Indivior’s SEC reporting history, monitor developments in its OUD pharmaceutical business, and interpret the financial and governance implications of its regulatory disclosures.
Indivior PLC furnished materials related to its latest results. The company issued a press release reporting financial results for the period ended September 30, 2025 and made accompanying presentation materials available on its website.
The press release was furnished as Exhibit 99.1, presentation materials as Exhibit 99.2, and an updated corporate presentation as Exhibit 99.3. The filing is signed by Chief Financial Officer Ryan Preblick.
Indivior PLC filed a report describing a press release issued on October 1, 2025 announcing its intent to redomicile from England and Wales to Delaware. The company explains that completing this move would require court approval in the U.K. and approval from its shareholders, and notes that timing, execution of its cost and capital reduction initiatives, and actions of third parties could all affect the outcome. Indivior characterizes these statements about redomiciling, potential timing, and potential benefits as forward-looking and highlights that actual results could differ materially due to various risks and uncertainties described in its recent Annual Report and Quarterly Reports filed with the SEC.
Form 144 notice for Indivior PLC (INDV): The filer notifies a proposed sale of 26,463 shares of Class A common stock through Merrill Lynch on 09/08/2025 with an aggregate market value of $655,000. The filing lists prior acquisitions of the shares: 13,805 shares bought on 03/26/2015 and 12,658 shares on 08/06/2019, both acquired on the open market for cash. The form also discloses sales by the same person within the past three months: 52,320 shares sold on 08/28/2025 for $1,278,178 and 30,000 shares sold on 09/04/2025 for $744,009.60. The filer certifies no undisclosed material adverse information and includes the required signature attestation.
Indivior PLC insider Mark Crossley filed a Form 144 notifying the proposed sale of 183,938 Class A common shares through J.P. Morgan Securities LLC on the NYSE, with an aggregate market value of $4,593,150.74 and an approximate sale date of 09/08/2025. The securities were acquired on 03/09/2025 upon vesting of restricted stock units from Indivior PLC (243,282 units). The filing also discloses two recent sales by the same individual: 52,320 shares sold on 08/28/2025 for $1,278,178 and 30,000 shares sold on 09/04/2025 for $744,009.60. The notice includes the standard representation that the seller is unaware of undisclosed material adverse information.
Two Seas Capital (and related persons) reported beneficial ownership of 10,329,152 Ordinary Shares of Indivior plc, representing approximately 8.3% of the company's outstanding shares. These shares are held directly by two funds (the "Litigation Fund" and the "Global Fund") and TSC has sole voting and investment power over the securities pursuant to Investment Management Agreements. Aggregate purchase prices disclosed are approximately $38,987,296 for 6,311,887 shares held by the Litigation Fund and $45,107,871 for 4,017,265 shares held by the Global Fund. The Litigation Fund purchases were financed in part by a Credit Facility provided by UBS AG, London Branch. The filing also notes the Global Fund no longer holds any cash-settled swap positions.
Form 144 notice for Indivior PLC (INDV) shows a proposed sale of 30,000 Class A common shares through J.P. Morgan Securities LLC on 09/04/2025 with an aggregate market value of $744,009.60. The filer reports acquiring 243,282 shares on 03/09/2025 by vesting of restricted stock units issued by Indivior PLC, paid as equity compensation. The filing also discloses a prior sale within the past three months: 52,320 shares sold on 08/28/2025 for gross proceeds of $1,278,178, attributed to Mark Crossley c/o Indivior PLC. The form includes a representation that the seller is not aware of undisclosed material adverse information.
Indivior PLC (INDV) submitted a Form 144 reporting a proposed sale of Class A common stock. The notice lists 52,320 shares to be sold through J.P. Morgan Securities LLC with an aggregate market value of $1,278,178 and an approximate sale date of 08/28/2025 on the NYSE. The filing shows these shares were acquired by vesting of restricted stock units: 243,282 shares vested on 03/09/2025 and 9,974 shares vested on 03/16/2025, both through equity compensation from Indivior PLC. The filer reports 124,769,536 shares outstanding and indicates there were no securities sold in the past three months by the selling person. The form includes the standard seller representation regarding absence of undisclosed material adverse information.
Indivior PLC announced a three-phase operational plan—the Indivior Action Agenda—focused on generating momentum through 2025 by growing SUBLOCADE in the U.S., simplifying the organization, and accelerating long-acting injectable penetration and SUBLOCADE net revenue thereafter. On August 26, 2025 the company began Phase 1 initiatives that include headcount reductions, real estate consolidations, and consulting, legal, and tax planning. Indivior estimates $39–$50 million of pre-tax restructuring charges (about $27–$35 million cash) to be recognized in Q3 and Q4 2025 and says it will exclude these charges from non-GAAP measures. The company is also exploring strategic alternatives for OPVEE and its non-U.S. business; further one-time costs and savings could result. Estimates are subject to change based on assumptions and execution.
Indivior PLC announced it entered into a new U.S.-style Employment Agreement and a Confidentiality, Proprietary Rights and Non-Competition Agreement with its Chief Financial Officer, Ryan Preblick, replacing his prior 2020 agreement. The company states there were no changes to his compensation, responsibilities, or title. The agreement specifies an annual base salary of $558,819, an annual cash bonus opportunity targeted at 60% of base salary (with a maximum opportunity of 120%), and potential long-term incentive awards with a grant-date value anticipated at 400% of base salary, subject to the Compensation Committee's discretion. The full agreements are filed as Exhibit 10.1 and Exhibit 10.2 and are incorporated by reference.
The filing reports that The Goldman Sachs Group, Inc. and its subsidiary Goldman Sachs & Co. LLC jointly beneficially own 9,789,169 ordinary shares of Indivior PLC, representing approximately 7.8% of the class. The statement shows shared voting power of 9,789,144 shares and shared dispositive power of 9,789,169 shares, with no sole voting or sole dispositive power reported.
Exhibits identify the GS Group as a parent holding company and Goldman Sachs & Co. LLC as a broker-dealer and registered investment adviser. The filing includes a joint filing agreement and a certification that the shares are held in the ordinary course of business and not for the purpose of changing or influencing control. The statement provides ownership disclosure but does not disclose acquisition terms or strategic plans.